Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and compared to a loss of $0.38 per share a year ago, representing an earnings surprise of 16.28% [1] - The company posted revenues of $243.97 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 9.24%, and compared to year-ago revenues of $185.62 million [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - The stock has added about 11.9% since the beginning of the year, underperforming the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the coming quarter is -$0.21 on revenues of $252.34 million, and for the current fiscal year, it is -$1.76 on revenues of $889.57 million [7] - The estimate revisions trend for Tandem Diabetes Care is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]